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In the recent past, it has repeatedly been reported that CD4 cells play an important role in the immunology of chronic myeloid
leukaemia. It was therefore of interest to test their activity in an animal model using bcr-abl-transformed cells. BALB/c mice were
four times immunized with a DNA vaccine carrying the bcr-abl fusion gene. Two weeks after the last vaccine dose, the animals
were challenged with syngeneic bcr-abl-transformed 12B1 cells which form solid tumors after subcutaneous administration. At the
time of challenge, animals were treated with antibodies against the CD8+ T cells or CD4+ T cells. The efficacy of the depletion was
monitored and found highly effective. All nonimmunized animals developed tumors. All animals untreated with the antibodies as
well as those in which CD8+ T cells had been depleted, were fully protected against the challenge. On the other hand, almost all
mice treated with anti-CD4+ antibody developed tumors. These results strongly suggested that the CD4+ T cells acted as effectors
in the present system.
1. Introduction
It is generally accepted that specifically activated CD8+ T
cells play the most important role in immunological tumor
rejection and a great majority of immunotherapeutic studies
have been focusing on them. In the recent past, it has
repeatedly been demonstrated that the CD4+ T cell response
is polyfunctional and there has been growing evidence that
a subpopulation of CD4+ T cells can mediate an efficient
antitumor activity in some systems (for review see [1, 2]).
Activated CD4+ T cells may partner with many different
t y p e so fh o s tc e l l st oc l e a rt h et u m o ri n d i r e c t l yb ys e c r e -
tion of vast array of cytokines. These cytokines react with
and activate distinct classes of cells including macrophages,
eosinophils, NK cells, and B cells and can induce antitumor
effect independent of CD8+ T cells [3].
Evidence of direct cytotoxic role for CD4+ T cells has
also been presented [4, 5]. Cytotoxic CD4+ T cells have been
detected in peripheral blood of subjects suffering from vari-
ous diseases such as those caused by viruses (HIV, CMV, and
EBV) (for review see [6]) and chronic inflammatory diseases
as rheumatoid arthritis [7]a n dB - c e l lc h r o n i cl y m p h o c y t i c
leukaemia[8].Ithasbeenshownthattheircytotoxiceffecthas
beenbasedonperforin-dependentpathway[9]and/oronthe
Fas-FasL-mediated apoptosis [10], and it has been suggested
that the lytic activity of CD4+ T cells is likely HLA class II
restricted, at least in some instances.
In our previous study, we have shown that it is possible
to induce solid immunity against the bcr-abl-transformed
mouse cells by immunization with a DNA vaccine carrying
the bcr-abl fusion gene [11]. It was the purpose of the present
study to identify effector cells responsible for the protection.
2. Methods
2.1. Cells. The mouse (BALB/c) 12B1 cells transformed by
human bcr-abl fusion gene [12] were used in the present
experiments. They were obtained through the courtesy of
E. Katsanis (University of Arizona, Tucson, AZ, USA) and
cultivated as described previously [13]. In brief, they induce
leukaemia-like disease after intravenous administration and2 Clinical and Developmental Immunology
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Figure 1: Flow cytometry analysis of splenocytes from animals (a) untreated and (b) treated with either rabbit polyclonal anti-CD4 or anti-
CD8 antibody. Animals received two doses of depletion antibodies in three-day interval and were sacrificed two days after the second dose.
The splenocytes were stained with rat monoclonal anti-CD4-FITC or anti-CD8-PE antibody.
solidtumorsaftersubcutaneousadministration.Theyexpress
MHC class I molecules and are of pre-B origin.
2.2. Animal Experiments. Seven-week old female BALB/c
mice were obtained from Charles Rivers, Germany. All
animal experiments were carried out in accordance with the
Guidelines for Animal Experimentation valid in the Czech
Republic. The human pBSC/bcr-abl [11]o rt h ee m p t yp B S C
[14] expression plasmids were used as DNA vaccines. DNA
cartridges were prepared according to the manufacturer’s
instructions (Helios Gene Gun System, Bio-Rad, Hercules,
USA). Using the gene gun, we applied 1𝜇go fD N Ao n
gold particles intradermally into the shaven abdominal area
four times at two-week intervals. For the challenge, 5 ×
10
3 12B1 cells (approximately 10 TID50)i n0 . 2m LP B Sw a s
administered s.c. into the flank area two weeks after the last
vaccination. Mice were monitored three times a week for up
to 90 days. When tumors reached the size of 400mm
2,t h e
mice were humanely sacrificed.
2.3. In Vivo Depletion of CD4+ and CD8+ T Cell Populations.
Mice were depleted of CD4+ or CD8+ T cell subsets, via
intraperitoneal administration of anti-CD4+ and anti-CD8+
antibodies (both rabbit polyclonal, purified IgG fraction,
Exbio, Prague, Czech Republic), respectively, 100𝜇L/dose (as
optimized in previous experiments). The antibodies were
administered 3 days before the challenge, at the time of
challenge (day 0) and then on days 7, 10, 17, and 24 after
the challenge. The efficacy of depletion was monitored by
flow cytometry two days after the second antibody dose and
challenge.
2.4. Flow Cytometric Analysis. After blocking nonspecific
binding with rat anti-mouse CD16/32 (BD Pharmingen,
San Diego, CA), splenocytes from antibody-treated and
u n t r e a t e dm i c ew e r el a b e l l e dw i t hm o n o c l o n a la n t i b o d i e s
FITC Rat Anti-Mouse CD4 (BD Pharmingen) or CD8a
( m o u s e )P E( E x b i o ) .Th er e d u c t i o no ft h er e s p e c t i v ec e l l
subsets was determined via comparison of antibody-treated
and control animals. To reveal other cell surface molecules,
12B1 cells were stained with monoclonal antibodies Anti-
Mouse CD95 (APO-1/Fas) PE (eBioscience, San Diego, CA,
USA), Anti-Mouse CD178 (Fas Ligand) PE (eBioscience),
FITC Anti-Mouse I-A
d (subclass of MHC II) (Cedarlane
Laboratories,Hornby, ON, Canada), and with corresponding
isotype controls (eBioscience and Cedarlane). In addition,
MHC class II expression by 12B1 cells was measured after
48hrsincubationofcellsinmediasupplementedwithmouse
recombinant IFN-𝗾 (200U/mL, Peprotech, London, UK).
Cells were examined by a LSR Fortessa flow cytometer (BD
Biosciences, San Jose, CA, USA). The results were analysed
using FlowJo 7.6 software.
2.5. Statistical Analysis. For the analysis of survival, the Log-
rank test was used. Calculations were done using Prism
Software Version 5.0 (Graph-Pad Software, San Diego, CA).
3. Results
3.1. Monitoring In Vivo Depletion. The results of the deple-
tion,obtainedwithsplenocytesofanimalssacrificedtwodays
after the second dose of the respective antibody, are shown
in Figure 1. Splenocytes from untreated animals served as
controls.ItcanbeseenthatbothCD8+andCD4+Tcellswere
nearly completely depleted, indicating that the procedure
used was highly effective.
3.2. Immunization Experiments. The results of the immu-
nization experiment are shown in Figure 2. The mice inoc-
ulated with the empty plasmid and subsequently treated or
untreated with depletion antibodies developed tumors and
died in all groups before day 25. Mice immunized with
pBSC/bcr-abl plasmid and untreated with antibodies were
fully protected against the challenge. Treatment with anti-
CD8 antibody did not render the animals susceptible to
tumor formation. On the other hand, 5 out of 6 immunized
micetreatedwithanti-CD4+antibodydevelopedtumorsand
died before day 25. The difference between mice depletedClinical and Developmental Immunology 3
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Figure 2: Survival of mice inoculated with empty pBSC or pBSC/bcr-abl plasmid and challenged with 12B1 cells. Six animals were in each
group. (a) Nondepleted, (b) depleted of CD8+ T cells, and (c) depleted of CD4+ T cells.
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Figure 3: Flow cytometry analysis of 12B1 cells for the expression of MHC class II, Fas (CD95) and FasL (CD178), (a) cells treated with anti-
MHC class II antibody, (b) cells cultivated in the presence of INF-𝗾 and treated with MHC class II antibody, (c) cells treated with anti-Fas
(CD 95) antibody, and (d) cells treated with anti-FasL (CD 178) antibody. Grey histograms indicate cells treated with the respective antibody.
Empty histograms represent cells treated with the appropriate isotype controls.
o fC D 8 +Tc e l l sa n dt h o s ed e p l e t e do fC D 4 +Tc e l l sw a s
statistically highly significant (𝑃 = 0.0054). The results
indicated that CD4+ T cells and not CD8+ T cells acted as
effectors in the present system. Similar data were obtained in
the repeated experiment.
3.3. Expression of MHC Class II, Fas, and FasL Molecules on
12B1Cells. Inordertogetinformationontheimmunerecog-
nition molecules which might be involved in the anticancer
effect,weusedflowcytometrytomeasurelevelsofexpression
o fM H Cc l a s sI I ,F a s ,a n dF a sLo nt h es u r f a c eo f1 2 B 1c e l l s .
The results are shown in Figure 3. It can be seen that these
cellsdonotexpresstheMHCclassIImoleculesandthattheir
expression was not induced by cultivation in the presence of
INF-𝗾. On the other hand, they do express Fas and very low
amounts of FasL.
4. Discussion
Quite recently it has been reported that SV40-induced
tumors could be eliminated by specifically activated CD4+ T
cells [15]. In those experiments, in which DNA vaccine was
used for immunization, depletion of CD8+ T cells did not
abolish the antitumor effect while depletion of CD4+ T cells
renderedmicesusceptibletotumorformation.Becauseofthe
timing of the immunization and subsequent administration
of antibodies used for depletion, it was evident that CD4+
T cells played a critical role both in the activation and the
effector phases. This was a rather surprising observation
because in the previous experiments carried out by the same
group of authors, in which they had immunized mice with
recombinant SV40 T antigen, the antitumor effect was medi-
ated through CD8+ T cells, with the possible contribution
of antibody-dependent cell cytotoxicity (ADCC) [16, 17]. In
addition,inthoseearlierexperimentstheyhaddemonstrated
that the CD4+ T cells were dispensable in the effector
phase.
The present experiments revealed that the immunity
against mouse bcr-abl-transformed 12B1 cells was mediated
through the activity of CD4+ T cells. Their removal resulted
in nearly complete abolishing of the anti-tumor immunity,
whilethedepletionofCD8+Tcellsdidnotimpairit.Because
of the timing of the depleting antibody administration, it4 Clinical and Developmental Immunology
seems clear that the CD4+ T cells were acting in the immune
effector phase. The mechanisms involved are not clear at
this writing. It is highly unlikely that the effect was directly
mediated through MHC class II molecules. The presence of
F a so nt h e1 2 B 1c e l l ss u g g e s t sb u td o e sn o tp r o v ea tt h i s
moment that Fas-FasL interaction was involved. However,
i ti sa l s op o s s i b l et h a tt h ee ff e c t sw eo b s e r v e dw e r ew i t h i n
the category of indirect effects induced by activated CD4+
Tc e l l sr e p o r t e di no t h e rs y s t e m s[ 1–3, 18, 19]. We also tried
to establish the possible role of NK cells in the present
undertaking. Using the same batch of antibody for depletion
of NK cells, the results of repeated test were inconsistent,
contributing—in a way—to the controversy about the role of
these cells in tumor rejection as recently discussed [20, 21].
The equivocation of our results concerning NK cells does
not seem to erode the conclusion that CD4+ T cells and not
C D 8 +Tc e l l sp l a y e dt h ed e c i s i v er o l ei nt u m o rr e j e c t i o ni n
the present system.
The present results are strongly reminiscent of the
previously mentioned data obtained in the SV40 system
[15]. It may be of interest that in both their and our studies,
DNA vaccines and BALB/c mice were employed. It will be
the purpose of the future experiments to find out whether
the vaccination constructs employed played any role in the
differentiation of CD4+ T cells into effector cells, whether
the mouse strain mattered, and whether the effects we
observed were associated with the presence of human
p210
bcr-abl in the mouse system or with the nature of the
tumor cells expressing this protein, the key element in
the pathogenesis of chronic myeloid leukaemia (CML).
There are some other indications that CD4+ T cells may
p l a yt h er o l eo fe ff e c t o r si nt h ei m m u n er e a c t i o n si nC M L .
For example, it has been reported that CD4+ T cell clones
isolated from several leukemic patients after bone marrow
transplantation (BMT) were cytotoxic for leukemic myeloid
cells but not for the other cells or cell lines [22]. It has also
been demonstrated that HLA-DR restricted CD4+ T cell
clones were cytotoxic for CML cells which processed and
presented exogenous antigen (PPD); this led the respective
authors to the conclusion that allogeneic donor CD4+ T
cells might be sufficient for the induction of graft-versus-
leukaemia (GvL) effect [23]. This seems to be in line with
the results of another study in which infusion of donor
CD4+ T lymphocytes depleted of CD8+ T lymphocytes
resulted in GvL effect in a large proportion of patients [24].
In a more recent study, all four T cell clones isolated from
CML patients after BMT, which had exhibited cytotoxicity
for autologous tumor cells, were immunophenotyped as
CD4+CD8− cells [25]. Also immune responses against
autologous tumor cells in imatinib-treated CML patients
were dominated by CD4+ T cells [26]. On the other hand,
there are observations militating against the role of activated
CD4+ T cells in eliminating leukemic cells. Thus, it has been
shown that the CD4+ T cells responding to exposure to
p210
bcr-abl-derived peptides in a HLA-restricted manner did
notexhibitcytotoxicactivity[27]andthatCD4+Tcellclones
isolated from healthy HLA-DRB1 individuals and reactive
with p210
bcr-abl-derived peptides paradoxically enhanced
the number of CML cell colonies when cocultivated
with CML cells obtained from HLA-DRB1 positive patients
[28]. In brief, there is now no really convincing evidence
on an important or even decisive role for CD4+ T cells
as effectors in anti-CML immunity. At this moment,
speculations on the role of CD4+ cells have a character of a
daring but testable hypothesis.
5. Conclusions
Without respect to the underlying mechanisms, the present
observationprovides somemoreammunitionforthe present
interest in the role for CD4+ T cells in effective phase
of antitumor immune responses. The results of this study
support the concept that CD8+ T cells do not command
the antitumor immunity in all instances. Definitely, the
role for CD4+ T cells as effectors in antitumor immunity
should be further intensively investigated, because—due to
the complex biology of these cells—many issues still remain
unexplained. The identification and characterization of their
subclass acting as cytotoxic effectors, if it really exists as
suggested [5, 29], may provide a boost for the future research
aimedatabetterunderstandingofthedeterminantsoftumor
immunogenicity and novel immunotherapeutic options.
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